Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)

The summary for the Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional): Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips are fast, sensitive, low cost and reasonably accurate. However, as there might not be testing strips for the new threats, the analysis must be performed via sensitive and sample agnostic methods.